Jeray Johnson, MD
Pulmonary Disease · Duluth, MNNPI 1629181706
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,600 of the $3,752 with a category attached, or 69.3%. GSK accounts for 84.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $3,143 and has fallen 94.1% since, to $187 in 2025.
Across 40 payments — averaging $93.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Philips North America LLC$146
- AstraZeneca$141
- Insmed, Inc.$95
- Verona Pharma, Inc.$47
- Mylan Specialty L.p.$43
- plus $115 from 7 others
What the payments were for
- Consulting fees$2,60069%
- Travel & lodging$38210%
- Food & beverage$73820%
- Education$321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $3,165 |
| Philips North America LLC | 9 | $146 |
| AstraZeneca | 8 | $141 |
| Insmed, Inc. | 5 | $95 |
| Verona Pharma, Inc. | 3 | $47 |
| Mylan Specialty L.p. | 2 | $43 |
| Amgen | 1 | $19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $19 |
| Baxter Healthcare | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$362
How this compares
$3,752 in reported general payments places this provider in the 85th percentile of 261 pulmonary disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 311 | $238,066 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 205 | $140,708 |
| SymbicortBudesonide/Formoterol Fumarate | 190 | $53,034 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 95 | $50,213 |
| Breo ElliptaFluticasone/Vilanterol | 112 | $48,454 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 68 | $47,577 |
| Spiriva RespimatTiotropium Bromide | 59 | $37,740 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 47 | $25,557 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 35 | $14,664 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $10,967 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $10,438 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 377 | $8,959 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $7,303 |
| EliquisApixaban | 11 | $6,881 |
| Arnuity ElliptaFluticasone Furoate | 11 | $6,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $3,165 | $350,923521 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $141 | $208,406430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 261 pulmonary disease providers in Minnesota.
Other pulmonary disease in Duluth
- Joseph MartinelliDuluth$7K
- Marshall HertzMinneapolis$289K
- David IngbarMinneapolis$272K
- Jonathan HovdaMinneapolis$139K
- Hilary DubrockRochester$102K
- Ulrich SpecksRochester$77K
- Hyun KimMinneapolis$77K
- Jagdeep BijwadiaRochester$54K
- Grady HedstromMinneapolis$50K
- Teng MouaRochester$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.